35 results about "Common cold" patented technology

Described are lipopeptides that inhibit coronavirus fusion to a host cell. Thus a therapeutic for treating or preventing the common cold is described along with methods of inhibiting and / or treating an alphacoronavirus infection. The lipopeptides comprise a peptide unit comprising an amino acid sequence having a high degree of sequence identity to a sequence from the C-terminal heptad repeat of a betacoronavirus S protein, such as that of SARS-CoV-2.

The collapsible saddle sleeper allows a person (e.g., adults or children) to collapse and transport the sleeper to any desired location to allow sleep in an angled position on their stomach (e.g., upper torso) and head in a straddle, sitting-like position, which helps reduce a variety of symptoms that are tied to specific medical conditions. In one example, the angled position may help a person to reduce and / or eliminate congestion and / or coughing while attempting to sleep when it's due to a common cold, flu or disease.

Embodiments of the disclosure include methods and compositions for treating the common cold in an individual or one or more symptoms thereof by administering fibroblasts and / or fibroblast-derived materials to an individual in need thereof. In specific embodiments, the fibroblasts (and / or fibroblasts from which the fibroblast-derived materials are derived) express one or more specific markers. In some embodiments, the fibroblasts (and / or fibroblasts from which the fibroblast-derived materials are derived) are exposed to one or more compounds prior to use, such as exposure to Poly IC.

This invention discloses a traditional Chinese medicine composition for improving fever in wind-heat common cold, belonging to the field of traditional Chinese medicine preparation technology. Addressing the shortcomings of existing Western medicines that suppress fever through central nervous system suppression, easily damaging organs and inhibiting microcirculation, and the limitations of traditional Chinese medicine preparations such as bitter and cold properties that astringe pathogens, causing low-grade fever rebound, damaging yin and spleen, and insufficient ability to resolve phlegm and strengthen the body, this invention innovatively combines the principles of monarch, minister, assistant, and guide herbs in a synergistic formulation based on the core microscopic pathogenesis of wind-heat common cold: "constriction of visceral microvessels, stagnation of heat pathogens, high fever depleting body fluids, fluid deficiency and blood stasis, and phlegm production due to stagnation." This invention is prepared using gardenia, platycodon, angelica, peppermint, ophiopogon, dandelion, lily, coix seed, and rehmannia as core raw materials. It utilizes pungent and dispersing herbs to open up the microcirculation of the body surface and lungs, dispersing stagnant heat and replacing the traditional bitter and cold heat-suppressing mechanism. Combined with heat-clearing and anti-inflammatory components, it targets and inhibits the release of inflammatory factors, resulting in stable fever reduction. Small doses of yin-nourishing herbs repair the damage to body fluids and blood caused by high fever, reversing the pathology of fluid deficiency and blood stasis. Spleen-strengthening and dampness-removing herbs harmonize the medicinal properties and strengthen the spleen. This invention achieves a balance of hot and cold properties, and addresses both tonification and purgation, providing a one-stop solution for complex symptoms such as fever, sore throat, nasal congestion, yellow phlegm, dry mouth, weakness, and fatigue caused by dampness in wind-heat colds. It provides stable fever reduction without rebound, and avoids the side effects of Western medicine and bitter and cold Chinese patent medicines. It addresses both the symptoms and the root cause, effectively avoiding post-cold sequelae and reducing the recurrence rate. Furthermore, the preparation process is simple, allowing for processing into various dosage forms, suitable for industrial mass production and widespread clinical application, possessing extremely high medical value and market potential.

The application discloses a traditional Chinese medicine composition for treating common cold by simultaneously resolving exterior and interior, and belongs to the technical field of traditional Chinese medicine compound. The application provides two groups of traditional Chinese medicine compositions which are used according to syndrome differentiation: the composition for treating wind-cold common cold is based on Xiaolingtang and Wuling San, and is combined with apricot kernel, purple yam, forsythia flower and the like; the composition for treating wind-heat common cold is based on Dalingtang, Wuling San and Houpu Dahuang Tang, and is combined with apricot kernel, radix trichosanthis and the like. According to the theory of cold damage of six meridians, the application divides the source of common cold into wind-cold and wind-heat, establishes the treatment method of simultaneously resolving exterior and interior, resolves exterior pathogen, regulates triple energizer and resolves internal pathogen, regulates the human body environment, and thus treats common cold. The application has the characteristics of simple and intuitive syndrome differentiation standard, reliable prescription combination, industrialized oral preparation, treatment of wind-cold common cold and wind-heat common cold, fast effect, wide indication and convenient use.

The present invention provides an aqueous solution composition capable of rapidly preventing, alleviating or eliminating symptoms of acute respiratory diseases by applying a hypertonic aqueous solution composition containing molecular iodine to all parts of the eyes, oral cavity, nasal cavity, and respiratory tract. The present invention provides a hypertonic aqueous solution composition containing molecular iodine, which can prevent and eliminate acute respiratory infectious diseases such as cold, flu, and COVID-19, and can rapidly alleviate or eliminate runny nose and nasal congestion caused by allergic and non-allergic rhinitis.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to application of MXA in preparation of a detection reagent for screening virus infection. The level of mucus virus resistance protein A (MXA) is detected by using a nasopharynx secretion sample, and a non-invasive diagnosis method for early stage (morbidity for 1-2 days) of common cold is carried out. The method can also be used for screening the risk of potential major viral infectious diseases (such as influenza or novel coronavirus infection and the like) with initial symptoms of common cold.

The present disclosure describes a method of treating a respiratory condition, wherein the respiratory condition is a respiratory enterovirus infection, an upper respiratory infection, a common cold, or a combination thereof, in a human subject with COPD which includes administering to the subject a therapeutically effective amount of vapendavir or a pharmaceutically acceptable salt thereof, thereby treating the respiratory condition in the subject. Pharmaceutical formulations of vapendavir and pharmaceutically acceptable salts thereof are also disclosed.

The invention belongs to the technical field of traditional Chinese medicines, and discloses a formula for preventing and treating new crown, influenza A and cold, which comprises the following components by weight: 12-17g of boat-fruited sterculia seed, 12-17g of grosvenor momordica fruit, 12-17g of dwarf lilyturf tuber, 8-12g of honeysuckle flower, 12-17g of wild chrysanthemum flower, 12-17g of sweet wormwood herb, 18-22g of mint and 12-17g of Chinese mosla herb. The formula disclosed by the invention is used for treating and preventing new crown influenza, influenza A, influenza, viral influenza and common cold, and is effective for pharyngeal pain, oral internal heat and gingival swelling.

This invention discloses a traditional Chinese medicine composition for treating acute and subacute cough after a cold and its application. The traditional Chinese medicine composition includes the following components: 10-15 parts of Perilla frutescens seed, 10-15 parts of Perilla frutescens stem, 10-15 parts of Paeonia lactiflora, 10-15 parts of processed Eriobotrya japonica leaf, 6-9 parts of Prunus armeniaca seed, 6-9 parts of Platycodon grandiflorus, 10-15 parts of Cinnamomum cassia twig, 10-15 parts of processed Pinellia ternata, 6-9 parts of Fritillaria cirrhosa, 15-30 parts of Poria cocos, 6-9 parts of Citrus reticulata peel, 6-9 parts of Citrus reticulata fibrosum, 9-15 parts of Scutellaria baicalensis, and 6-9 parts of processed Glycyrrhiza uralensis. The traditional Chinese medicine composition of this invention follows the core treatment principle of "promoting lung function and relieving cough, resolving phlegm and soothing the throat, and clearing away residual pathogens". Targeting the pathogenesis characteristics of acute and subacute cough after a cold, the principal and assistant herbs directly target the core symptoms of cough, quickly relieving acute manifestations such as cough and sore throat; the adjuvant herbs work on multiple targets, taking into account resolving phlegm, clearing heat, and unblocking the meridians, adapting to different syndrome types and disease stages, and preventing prolonged cough; the guiding herbs harmonize the properties of the herbs, mildly protect the body's vital energy, avoid the harshness of the medicine damaging body fluids, and at the same time eliminate the source of phlegm production.

Provided are a traditional Chinese medicine composition and a method for preparing same. The composition is prepared from the following raw materials and optionally a pharmaceutically acceptable excipient. The raw materials include: Astragali Radix, Lonicerae Flos, Saposhnikoviae Radix, Cinnamomi Ramulus, Paeoniae Alba Radix, Forsythiae Fructus, Atractylodis Macrocephalae Rhizoma, Platycodonis Radix, Zingiberis Rhizoma, Jujubae Fructus, Citri Reticulatae Pericarpium, Isatidis Radix, and Glycyrrhizae Radix et Rhizoma. The composition can be used for preparing a medicament for treating common cold, viral infection, fever, inflammation, or cough, for relieving phlegm, for relieving pain, for immunoregulation, or for protecting influenza A close contacts.

The invention discloses a traditional Chinese medicine combined prescription for livestock diseases and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine combined prescription for livestock diseases is prepared from the following traditional Chinese medicines in parts by weight: gypsum, radix rehmanniae, radix scrophulariae, radix isatidis, folium isatidis, cortex phellodendri, scutellaria baicalensis, coptis chinensis, gardenia jasminoides, rhubarb, rhizoma anemarrhenae, platycodon grandiflorum and liquorice. When the prescription is prepared into a veterinary drug, the prescription further comprises pharmaceutically acceptable auxiliary materials, and the auxiliary materials are selected from one or more of starch, dextrin, cane sugar and microcrystalline cellulose. The dosage form of the prescription comprises powder, granules or oral liquid. Through scientific proportioning, a multi-target synergistic effect system of antipyretic-antiviral-antibacterial-immunoregulation is formed, various compound diseases such as wind-heat type common cold and pneumonia of livestock can be treated at the same time, the complexity of repeated medication of a single disease is reduced, the prevention and treatment efficiency is improved, various livestock diseases are comprehensively prevented and treated, the types of medication are reduced, and the breeding efficiency is improved.

This invention discloses a pharmaceutical composition for treating pediatric colds with stagnation, its preparation method, and its uses. It is a preparation made from active ingredients and pharmaceutically acceptable excipients. The active ingredients are prepared from the following raw materials in the indicated weight ratios: Ephedra 4-7 parts, Bitter Almond 5-8 parts, Mulberry Bark 5-8 parts, Lycium Bark 7-10 parts, Peppermint 4-7 parts, Tangerine Peel 4-7 parts, Areca Peel 7-11 parts, Malt 10-14 parts, and Licorice 3-6 parts. The preparation is obtained by decoction with water, or by decoction with water to obtain an extract, followed by distillation to extract the volatile oil. The extract and volatile oil are then combined to obtain the final preparation. This pharmaceutical composition is widely used clinically to treat pediatric colds with stagnation, particularly pediatric colds with wind-cold and stagnation, with definite efficacy. It can also be used in the preparation of medicines for preventing and treating pediatric colds with stagnation.

The invention discloses a traditional Chinese medicine composition for treating cold, body deficiency and cough and application thereof, and relates to the technical field of traditional Chinese medicine, codonopsis pilosula, notopterygium root and radix angelicae pubescentis are adopted as monarch drugs, codonopsis pilosula is used for tonifying spleen qi and supporting healthy qi, notopterygium root and radix angelicae pubescentis are combined to treat rheumatism pain of the whole body, radix bupleuri and ligusticum wallichii are adopted as ministerial drugs to dredge superficies, bring down fever, activate blood and promote qi circulation, and the traditional Chinese medicine composition has the effects of relieving rheumatism and relieving pain. Peucedanum praeruptorum, platycodon grandiflorum, fructus aurantii, poria cocos, scorched hawthorn fruit, scorched malt and scorched medicated leaven are used as adjuvant drugs to depress qi and reduce phlegm, disperse wind heat, disperse lung and relieve sore throat, regulate qi and relieve chest stuffiness, remove food retention and distension, tonify spleen and excrete dampness, calm heart and tranquilize mind, promote digestion and harmonize stomach, and liquorice, ginger and mint are used as conductant drugs to harmonize the drugs, disperse wind cold and clear heat. And the traditional Chinese medicine composition is mainly used for treating qi deficiency and exogenous wind-cold-dampness syndromes.

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to sugar-free traditional Chinese medicine granules for treating wind-heat type common cold and a preparation method of the sugar-free traditional Chinese medicine granules. The sugar-free traditional Chinese medicine granules for treating wind-heat type common cold are prepared by extracting mint, schizonepeta spike, burdock, radix isatidis, fructus forsythiae, folium mori, rhizoma phragmitis, chrysanthemum, semen armeniacae amarae, ramulus mori and medicated leaven as raw materials. The weight part ratio of the raw materials is 3: (2-3): 3: (4-5): 3: 3: 3: 3: 3: 3: 3: 3; wherein the burdock extract is an alcohol extract, and the content of arctiin in the alcohol extract is not less than 10% by mass. The sugar-free traditional Chinese medicine granules for treating wind-heat type common cold have higher arctiin content, and have advantages in extraction of burdock and utilization of active ingredients compared with wind-heat type common cold granules prepared by a traditional process.

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of suspension which comprises the combination of ibuprofen and phenylephrine, or a pharmaceutically acceptable salt thereof, as active substances, and hypromellose, xanthan gum, liquid maltitol, glycerine and water. The composition is stable, has good organoleptical properties and shows excellent pharmacokinetic profile, providing quick absorption of the drugs. The present invention also relates to the use of the composition for treating the symptoms of flu and common cold, particularly in adults and in children over 7 years.

This invention belongs to the field of in vitro diagnostic technology, specifically the use of MXA in the preparation of a test reagent for identifying viral infections. This method utilizes nasopharyngeal secretion samples to detect myxovirus resistance protein A (MXA) levels, enabling a non-invasive diagnosis of the common cold in the early stages (1-2 days after onset). This method can also be used to screen for the risk of potentially serious viral infectious diseases (such as influenza or novel coronavirus infection) with early common cold-like symptoms.

The invention relates to a traditional Chinese medicine composition for treating common cold or flu and a preparation method thereof, the traditional Chinese medicine composition is prepared from the following components in parts by weight: 398-807 parts of kudzuvine root, 263-524 parts of ephedra, 279-536 parts of cassia twig, 799-1519 parts of lalang grass rhizome, 252-542 parts of fried bitter apricot kernel, 252-542 parts of rhizoma zingiberis and 252-542 parts of liquorice. 276-516 parts by weight of dried ginger and 163-311 parts by weight of licorice root; the traditional Chinese medicine composition is mainly used for relieving exterior syndrome, dispelling cold, promoting salivation, relaxing tendons, ventilating lung and relieving cough.

To provide a compound of formula (I) as described herein, pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods for using these compounds, salts, and compositions to treat viral infections. [Solution] The present invention relates to a novel 1,3-dioxoindene compound that is an inhibitor of picornaviruses, including coxsackievirus, enterovirus, echovirus, poliovirus, and rhinovirus, and is therefore useful for treating viral infections, including polio, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular diseases, hepatitis A, myositis, myocarditis, pancreatitis, diabetes mellitus, epidemic myalgia, encephalitis, common cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis, or otitis media.

The invention relates to a traditional Chinese medicine composition for treating common cold or influenza and a preparation method thereof, the traditional Chinese medicine composition is prepared from 5-30 parts by weight of honeysuckle, 5-30 parts by weight of fructus forsythiae, 1-20 parts by weight of radix bupleuri, 1-20 parts by weight of radix puerariae, 1-15 parts by weight of mint, 1-10 parts by weight of honey-fried ephedra and 1-5 parts by weight of licorice. The traditional Chinese medicine composition has a good effect of treating viral pneumonia caused by influenza viruses, and the preparation method of the traditional Chinese medicine composition is simple and suitable for large-scale production and popularization.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to granules for treating infantile common cold and a preparation method thereof. According to the present invention, the prescription research is performed aiming at the poor taste of the children's cold granules in the market, and the preparation method and the processing mode are adjusted, especially the whole volatile oil inclusion process is optimized; the problems of odor influence caused by volatile oil components such as pogostemon cablin and mint in the prescription and bitterness caused by isatis root and rehmannia are effectively solved.

The present invention relates to a liquid pharmaceutical composition for oral administration in the form of a suspension, comprising a combination of ibuprofen and phenylephrine or pharmaceutically acceptable salts thereof as active ingredients, as well as hypromellose, xanthan gum, liquid maltitol, glycerol, and water. The composition is stable, has good organoleptic properties, and exhibits an excellent pharmacokinetic profile, providing rapid absorption of the drug. The present invention also relates to the use of the composition for treating symptoms of influenza and the common cold, particularly in adults and children over 7 years of age.

This invention discloses a traditional Chinese medicine composition for treating wind-heat type common cold and its preparation method, relating to the field of traditional Chinese medicine technology. The composition is made from the following raw materials in parts by weight: 15-20 parts of *Ilex asprella*, 10-15 parts of mulberry leaf, 4-10 parts of wild chrysanthemum, 4-10 parts of *Viola yedoensis*, 10-15 parts of *Senecio scandens*, and 4-10 parts of dandelion. The preparation method includes: mixing the raw materials, soaking in 6-10 times the amount of water for 15-60 minutes; decocting twice, maintaining the boil for 1.5-2 hours each time, filtering and combining the filtrates; concentrating to a relative density of 1.14-1.18 at 80°C, cooling, adding 95% ethanol to achieve an alcohol content of 65-70%, stirring and standing for 12-24 hours, collecting the supernatant; recovering the ethanol under reduced pressure to obtain an extract and concentrating to a relative density of 1.25-1.30 at 80°C. This invention solves the problems of existing drugs for treating wind-heat colds having a narrow range of indications, insufficient extraction of effective components or incomplete removal of impurities in the preparation process, and the need to improve product quality stability.

Compositions and methods of treating a coronavirus infection in a subject are provided. The methods generally include administering to the subject an effective amount of a probenecid, metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can be therapeutic and / or prophylactic. The amount of probenecid, metabolite or analog thereof, or a pharmaceutically acceptable salt thereof can be effective, for example, to reduce viral replication, reduce one or more symptoms of a disease, disorder, or illness associated with the virus, or a combination thereof. In preferred embodiments, the virus is a severe acute respiratory syndrome-associated coronavirus, such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-associated coronavirus, such as MERS-CoV, or a coronavirus that causes the common cold.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to application of MXA in preparation of a detection reagent for screening virus infection. The level of mucus virus resistance protein A (MXA) is detected by using a nasopharynx secretion sample, and a non-invasive diagnosis method for early stage (morbidity for 1-2 days) of common cold is carried out. The method can also be used for screening the risk of potential major viral infectious diseases (such as influenza or novel coronavirus infection and the like) with initial symptoms of common cold.

The present disclosure provides a method of identifying and / or quantifying a perceived immune fitness of an individual. The method comprises identifying a frequency and / or a severity of one or more conditions experienced by an individual. The one or more conditions includes sore throat, headaches, flu, runny nose, coughing, cold sores, boils, mild fever, warts, pneumonia, bronchitis, sinusitis, sudden high fever, ear infection, diarrhea, meningitis, eye infection, sepsis, long healing injuries, shortness of breath, skin problems, muscle and joint pain, and common cold. The method further includes calculating a perceived immune fitness score of the individual based on up to 10 of the one or more conditions with the highest frequency and / or severity.

The application provides a method and a cold mask for rapidly treating cold by traditional Chinese medicine fumigation, and belongs to the fields of traditional Chinese medicine and traditional Chinese medicine materials. The fumigation traditional Chinese medicine composition for treating cold and an oxidizing agent are added into the mask, so that the effective substances of the traditional Chinese medicine composition and the oxidizing agent are gasified in the mask, and the gasification product is used for fumigating the respiratory tract; the drug is targeted to the site, and a very low dosage can kill bacteria, fungi, spores and viruses (including the novel coronavirus) in the respiratory tract, repair the respiratory tract mucosa lesion and improve the human body resistance, so that the cold is rapidly treated; and the single protection function of the existing mask is changed into a protection and treatment dual function.

The invention discloses a traditional Chinese medicine composition for treating new crown cold and cough. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicinal materials: radix paeoniae alba, poria, fingered citron, radix curcumae, szechwan chinaberry fruit, herba artemisiae scopariae, pericarpium arecae, liquorice, fructus xanthii, fermented soybean, fructus forsythiae, radix scutellariae, radix saposhnikoviae, pericarpium trichosanthis, platycodon grandiflorum, radix stemonae, radix asteris, tussilago farfara, plantain herb, South African leaf, radix bupleuri and schizonepeta spike. The invention relates to the technical field of traditional Chinese medicines, particularly provides a traditional Chinese medicine composition capable of effectively treating various compound symptoms such as severe cough, hemoptysis, headache, dizziness and low fever caused by viral respiratory tract infection at the same time, and solves the problem of inaccurate conversion of medication dosage for children at the same time.

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory -based disease and disorders comprising administration of ImmunoFolate.

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as coronavirus colds and as a therapy against COVID-19. ImmunoFolate has been shown to reduce the incidents of colds and flus. In one embodiment is a method of treating cancer comprising administration of ImmunoFolate. In another embodiment is a method of treatment inflammatory-based disease and disorders comprising administration of ImmunoFolate.